Stelara (Ustekinumab) receives FDA Approval for Treatment of Moderate to Severe Plaque Psoriasis with Four-Times-A-Year Maintenance Dosing Johnson&Johnson, 25 Sep 2009 Accessed on 13 Dec 2011 from http://www.jnj.com/connect/news/all/20090925_150000. CommentRecommendBookmarkWatch